If you typed “is compounded semaglutide still legal in 2026” into Google with a knot in your stomach, first, take a breath. You’re not behind, you haven’t done anything wrong, and you’re not about to get in trouble. The rules around compounded GLP-1s did change this year, and the headlines have been loud and honestly a little scary. So I sat down and read the actual FDA notice and the Federal Register filings, the dense forty-page version, so I could hand you the calm, sourced picture instead of the panic one.
I’ve been on a compounded GLP-1 for two years, and I’ve walked a lot of other women through their access, so I know exactly what that pit in your stomach feels like when it seems like the thing that’s been working might get pulled out from under you. I’m an ISSA-certified nutritionist and personal trainer, but on this topic I’m also just someone with skin in the game like you. Here’s what’s actually happening, what it means for your next refill, and what I’d do if I were starting over today.
Quick disclosure: one provider link below is an affiliate link, so I may earn a small commission at no cost to you. I only recommend providers I’d point a friend to.
The short answer
Yes. As of [Month] 2026, you can still legally get compounded semaglutide, as long as it’s made by a state-licensed pharmacy for you specifically and prescribed by a licensed provider. But the pathway is narrowing. The FDA is moving to permanently close the large-scale compounding route, the public comment period closed on July 30, 2026, and a final decision hasn’t been announced yet.
What actually happened
To understand where things stand, it helps to know how compounded GLP-1s became so widely available in the first place. When demand exploded, the branded manufacturers couldn’t keep up, and the FDA placed semaglutide and tirzepatide on its drug shortage list. Under the law, a shortage listing temporarily opens the door for compounding pharmacies to make their own versions. That single exception is what built the entire compounded GLP-1 industry.
Then the shortages ended. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. That’s the hinge point. Once a drug comes off the shortage list, the temporary permission that made large-scale compounding legal starts to close.
On April 30, 2026, the FDA went further. It proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying it did not identify a clinical need for large outsourcing facilities to compound these drugs from bulk ingredients. The proposal opened for public comment on May 1, was extended by 30 days in June, and that comment period closed on July 30, 2026. As I’m writing this, the FDA has not announced a final decision, and nobody outside the agency knows the exact timeline.
Why the pharmacy matters more than the provider
Here’s the piece almost nobody explains, and it’s the most important thing in this whole post: your pharmacy matters as much as your provider. Maybe more.
Think about it this way. Your provider is the face of the whole thing. They’re the licensed person who reviews your intake and writes your prescription, and they absolutely matter. But the pharmacy is where your medication is actually made. It’s the source. Two people can use the very same telehealth provider and end up with medication from completely different pharmacies. And in 2026, the type of pharmacy is what determines how these new rules land on you personally.
So while everyone’s busy asking “which provider should I use,” the sharper question, the one that actually protects you right now, is “where does my medication actually come from.” That brings us to two terms you’re going to keep running into.
503A vs 503B, explained simply
There are two categories of compounding pharmacy, and the difference between them is the whole story right now.
A 503B pharmacy is a large outsourcing facility. These make big batches at industrial scale, and they’re what powered the mass availability of low-cost compounded GLP-1s. The FDA’s proposal is aimed squarely at this route. If it’s finalized as written, 503B facilities would be permanently barred from compounding semaglutide and tirzepatide from bulk ingredients, with no path to reopen it even if a new shortage appeared.
A 503A pharmacy is a state-licensed pharmacy that compounds a medication for a specific patient, based on a specific prescription. This is the older, more traditional model, and it operates under a different part of the law. Patient-specific 503A compounding is a separate pathway, and it is not what this proposal shuts down.
So here’s the honest picture: the industrial-scale route is closing, and the patient-specific route is narrower and under pressure but still open. Which of the two your medication comes from is exactly why knowing your pharmacy matters so much. Transparency about the pharmacy is also one of the biggest green flags I look for in a provider, and I wrote a whole guide on vetting providers if you want the full checklist.
(Internal link to Post 2: How to Choose a GLP-1 Telehealth Provider.)
So is compounded semaglutide still legal in 2026?
Yes, with the nuance you now understand. Right now, you can still legally get compounded semaglutide when it’s made by a state-licensed pharmacy, for you specifically, prescribed by a licensed provider. What’s disappearing is the large-scale, bulk-compounded supply that made it so cheap and so widely available.
One thing I’ll always be straight with you about: compounded medications are not FDA-approved, and they are not reviewed by the FDA for safety, effectiveness, or quality. That’s true no matter which pharmacy makes them, and it’s a real part of the tradeoff to weigh with your provider. I say that not to scare you, but because you deserve the full picture instead of a sales pitch.
What this means for your access and your cost
If your current medication comes from a 503B facility, you’re the most likely to feel a change, whether that’s a supply hiccup, a price shift, or your provider quietly moving you to a different pharmacy. If it comes from a 503A pharmacy, you’re on relatively steadier ground for now, though “for now” is doing real work in that sentence.
The genuinely good news is that your options have grown, even as the compounded route narrows. Branded medications are more reachable than they were a year ago. Zepbound runs roughly $299 to $449 a month through LillyDirect, Wegovy is around $349 a month through the manufacturer’s cash program, and there are now oral options in the ballpark of $149 a month. And if you or a parent is on Medicare, the new GLP-1 Bridge program that started in July 2026 caps copays at $50 a month for qualifying patients. I broke down the full cost picture, including how the Medicare Bridge program works, and the new oral pill in their own posts.
(Internal links to Post 5: cost, and Post 19: oral pill.)
What I’d do right now
If you’re on a compounded GLP-1 today, here’s my honest, non-panicky advice.
Don’t stockpile. Hoarding medication isn’t safe and it isn’t necessary.
Ask your provider two direct questions: what kind of pharmacy fills my prescription, and how are you adapting to the 2026 rules? A provider who answers those clearly is showing you exactly the transparency you want. One who gets vague or defensive is telling you something too.
Know your options before you need them. Compliant compounded care, branded, oral, insurance, and Medicare are all on the table, and you have more paths than the headlines suggest.
And if your provider goes quiet or dodges your questions, you are allowed to move. Switching is common and usually simple, and you don’t lose your progress by doing it.
(Internal links to Post 1 and Post 2.)
The provider I’d trust in this environment
If you’re choosing where to be right now, I’d want a provider that works with state-licensed 503A pharmacies and is transparent about it. OrderlyMeds is the one I’d point to here, because they work exclusively with 503A pharmacies, which is the patient-specific pathway this proposal doesn’t target. That, plus budget-friendly month-to-month pricing and no lock-in, makes it my pick for this particular moment. Check out OrderlyMeds here, and use coupon code BIOHACKER25 for a discount.
I want to be fully transparent about another provider I like, because it matters in this exact context. GobyMeds is a solid option for a lot of people, but at the time of writing this, they use a mix of 503A and 503B pharmacies. So when selecting which pharmacy (they do give you the option usually) just know that if you select one that is a 503B, you might end up having to switch down the road once they remove the 503B options. But Goby does have 503A options so you wouldn’t need to find a whole new provider persay. Check out GobyMeds here, and use coupon code EDIT25 for a discount.
What happens if the rule is finalized?
If the FDA finalizes its proposal as written, the large-scale 503B bulk route for these medications closes permanently, with no future path to reopen it even in a new shortage. Patient-specific 503A compounding would likely continue, but under ongoing pressure and scrutiny. And branded, oral, and insurance-covered options would become the mainstream way most people access GLP-1s. That’s the direction of travel. The one thing I can’t give you is a firm date, because the FDA hasn’t set one, and anyone claiming certainty about the timing is guessing.
The bottom line
You are not out of options, and you have not missed your window. Compounded semaglutide is still legal right now through the right pharmacy, the branded and oral paths are more affordable than they used to be, and the single most useful thing you can do today is find out where your medication actually comes from. Ask the pharmacy question. Everything else gets easier once you know the answer.
This is a developing story and will be updated as the FDA issues a final decision. This article is for education and is not medical or legal advice. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always talk with a licensed provider before starting, stopping, or changing any medication. Last updated: August 2026.
One Comment